BRAF mutations have been extensively studied in CRC, and have been strongly associated with poor outcomes in metastatic tumors [27], particularly with respect to the classical BRAF p.V600E; non-V600E mutations seem to confer favorable prognosis [35], which was indicated in the few such patients in our series as well. This evidence concerns the gene BRAF and metastatic neoplasm.